Life Science Intelligence

Under the direction of Founder and CEO Melissa Krebs, PhD, GelSana is developing a novel class of synthetic polymers designed to address two of the most persistent barriers in chronic wound healing: inflammation and infection. Built on more than a decade of biomaterials research, the company’s technology is engineered to help calm inflammation, repel bacteria, and create an optimal environment for wound healing. With strong preclinical results, nearly $6 million raised to date, and its first product, CleraFlex™ Stretchable Wound Dressing, expected to launch imminently, GelSana is entering a large and rapidly evolving wound care market with a fundamentally new materials platform. Origin Story GelSana’s technology originated in the academic lab of Melissa Krebs, PhD, who has spent her career researching biomaterials and translational medical technologies. The polymers that now form the foundation of GelSana were developed and refined in her lab over more than a decade. “I’ve been doing b...

The company received a CE Mark label expansion for its FARAPULSE platform , allowing the pulsed-field ablation system to treat patients with persistent atrial fibrillation (AFib). The approval covers the FARAWAVE and FARAWAVE NAV catheters and follows results from the ADVANTAGE AF clinical trial, where the technology met its primary safety and efficacy endpoints. The update arrives at an important moment for pulsed-field ablation . The PFA market only began to take shape in 2024, yet competition has intensified quickly. Expanding indications represent one of the most direct ways for companies to grow their share of this rapidly developing market. Before looking at how the competitive landscape is shifting, it helps to understand what the persistent AFib indication adds to the overall opportunity. Expansion of the Addressable AFib Population AFib affects an estimated 60 million people worldwide, according to the Global Burden of Disease study. Clinically, these patients are typically gr...

  Medtech deal activity   continues to move quickly, and the latest transaction highlights growing momentum in interventional oncology. This week, Quantum Surgical acquired NeuWave Medical from Johnson & Johnson. Financial terms were not disclosed, but the strategic implications are clear. Quantum Surgical’s expertise in robotic assistance and navigation will now be combined with NeuWave’s Microwave Ablation System under a new organization called Precision IO Group. The company will be led by Kurt Azarbarzin, a medtech executive whose background includes leadership roles at Verb Surgical,  EndoQuest Robotics , and SurgiQuest. For Johnson & Johnson, the transaction reflects continued efforts to streamline its portfolio and concentrate on higher-growth segments. For  Quantum Surgical , the acquisition provides both a proven technology platform and direct access to a large installed base of leading cancer centers. To understand why the deal matters, it helps to ...